Silverarc Capital Management’s Abeona Therapeutics ABEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.77M Sell
610,407
-38,535
-6% -$212K 0.39% 55
2026
Q1
$2.91M Buy
648,942
+21,204
+3% +$106K 0.3% 52
2025
Q4
$3.31M Sell
627,738
-367,016
-37% -$1.85M 0.46% 50
2025
Q3
$5.25M Buy
994,754
+76,856
+8% +$487K 0.71% 38
2025
Q2
$5.21M Buy
+917,898
New +$5.22M 0.96% 29

Other funds holding ABEO

Silverarc Capital Management's ABEO Position: Q2 2026 in Review

Silverarc Capital Management reduced its Abeona Therapeutics (ABEO) stake by 5.9% in Q2 2026, selling an estimated $212K and leaving 610,407 shares worth $3.77M. The position accounts for 0.39% of the portfolio, ranked #55.

Silverarc Capital Management first reported a position in ABEO in Q2 2025 and has held it in 5 quarters since. The position peaked at $5.25M in Q3 2025. 126 funds tracked by Wall St. Rank hold ABEO as of Q2 2026.

  • Silverarc Capital Management held 610,407 shares of Abeona Therapeutics worth $3.77M as of Q2 2026.
  • Silverarc Capital Management sold 38,535 Abeona Therapeutics shares in Q2 2026, an estimated $212K.
  • Abeona Therapeutics made up 0.39% of Silverarc Capital Management's portfolio in Q2 2026, its #55 holding.
  • Silverarc Capital Management first reported a position in Abeona Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Silverarc Capital Management's Abeona Therapeutics position peaked at $5.25M in Q3 2025.
  • 126 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q2 2026.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.